<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Technetium Tc-99m tilmanocept: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Technetium Tc-99m tilmanocept: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Technetium Tc-99m tilmanocept: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="88729" href="/d/html/88729.html" rel="external">see "Technetium Tc-99m tilmanocept: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20322771"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lymphoseek</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F50124955"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Radiopharmaceutical</span></li></ul></div>
<div class="block dop drugH1Div" id="F55830591"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The route of administration, number of injections, and total injection volume per patient will vary depending on cancer and planned injection technique.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0501334-27a3-49b5-88b5-5a2dd3e56772">Lymphatic mapping, primary solid tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphatic mapping, primary solid tumor:</b> Infants, Children, and Adolescents: Intradermal, SUBQ, or peritumoral: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative lymphatic mapping.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55830592"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F55830593"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F20321325"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="88729" href="/d/html/88729.html" rel="external">see "Technetium Tc-99m tilmanocept: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>The route of administration, number of injections, and total injection volume per patient will vary depending on cancer and planned injection technique.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ea92bb4-07fb-4993-8f2d-b8a9c169612f">Breast cancer lymphatic mapping</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer lymphatic mapping:</b> Intradermal, SUBQ, subareolar, or peritumoral: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative lymphatic mapping.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42a28436-9d1c-4b63-8f6e-71cef89484fc">Melanoma lymphatic mapping</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma lymphatic mapping:</b> Intradermal or SUBQ: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative lymphatic mapping.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e221e6f-3cdb-435c-9f33-d1106c20dcf3">Oral cavity squamous cell carcinoma sentinel lymph node biopsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral cavity squamous cell carcinoma sentinel lymph node biopsy:</b> Peritumoral: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative sentinel node biopsy.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991164"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50988529"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F20322940"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Irritation at injection site, pain at injection site</p></div>
<div class="block coi drugH1Div" id="F20321310"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F20321311"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions with technetium Tc 99m tilmanocept may be possible (due to a chemical similarity to dextran), although no serious cases of hypersensitivity were reported in clinical trials. Medications and equipment for management of hypersensitivity should be available during administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Radiating-emitting products may increase the risk for cancer, particularly in children.   </p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Intended to supplement palpation, visual inspection, and other traditional lymph node localization procedures. Lymphatic drainage and function may be altered by prior surgery, radiation, edema, inflammation, or metastatic disease. Alterations in the lymphatic system may result in changes to node localization. Avoid injections into biopsy wound areas with evidence of edema or inflammation.</p></div>
<div class="block foc drugH1Div" id="F20323579"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lymphoseek: Tilmanocept 250 mcg [vial contents to be combined with Technetium Tc 99m pertechnetate sodium (not included)] [contains phenol]</p></div>
<div class="block geq drugH1Div" id="F20321305"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block accres drugH1Div" id="F20321335"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Lymphoseek may only be obtained through Cardinal Health’s Nuclear Pharmacy Services.</p></div>
<div class="block admp drugH1Div" id="F55830598"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Route of administration (intradermal, subcutaneous, or peritumoral) is determined by cancer and planned injection technique; dose may be administered as a single injection or as multiple injections. In adults with breast cancer, subareolar injections can be used.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer at least 15 minutes prior to intraoperative lymphatic mapping and sentinel lymph node biopsy; complete mapping or sentinel node biopsy within 15 hours from administration. Use a handheld gamma counter to identify radioactivity concentrated within lymph nodes (refer to manufacturer's instructions for further details). Avoid injections into biopsy wound areas with evidence of edema or inflammation.</p></div>
<div class="block adm drugH1Div" id="F20321329"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Route of administration (intradermal, subcutaneous, subareolar, or peritumoral) is determined by cancer and planned injection technique; dose may be administered as a single injection or as multiple injections.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast cancer lymphatic mapping: May be administered by intradermal, subQ, subareolar, or peritumoral injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Melanoma lymphatic mapping: May be administered by intradermal or subQ injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral cavity squamous cell carcinoma sentinel lymph node biopsy: May be administered by peritumoral injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24051744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24051744'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">Administer at least 15 minutes prior to intraoperative lymphatic mapping and sentinel lymph node biopsy; do not delay mapping or sentinel node biopsy more than 15 hours beyond administration. Use a handheld gamma counter to identify radioactivity concentrated within lymph nodes (refer to manufacturer’s instructions for further details). Avoid injections into biopsy wound areas with evidence of edema or inflammation.</p>
<p style="text-indent:0em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p></div>
<div class="block sts drugH1Div" id="F20321314"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-top:0em;display:inline">Store kit at 20°C to 25°C (68°F to 77°F); excursions permitted at 15°C to 30°C (59°F to 86°F). Keep in original package. Once reconstituted, keep in radiation shielding at room temperature. Use radiolabeled product within 6 hours of preparation; discard unused portion. </p></div>
<div class="block usep drugH1Div" id="F53571064"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Radioactive diagnostic agent indicated with or without scintigraphic imaging (using a handheld gamma counter) for:</p>
<p style="text-indent:-2em;margin-left:4em;">- Lymphatic mapping to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management (FDA approved in ages ≥1 month and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">- Guiding sentinel lymph node biopsy in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer, or melanoma (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F16338549"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F20344385"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F20344383"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53483542"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to administration in women of childbearing potential (EANM/SNMMI [Giammarile 2013]; SNM 2010).</p></div>
<div class="block pri drugH1Div" id="F20321307"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Unbound technetium crosses the placenta. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR/SPR 2018; Adelstein 1999; EANM/SNMMI [Giammarile 2013]; ICRP 2000; SNM 2010).</p></div>
<div class="block mopp drugH1Div" id="F55830601"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F20321316"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent which accumulates in lymphatic tissue and binds (selectively) to a mannose binding receptor (CD206) on macrophage and dendritic cell surfaces.</p></div>
<div class="block phk drugH1Div" id="F20321318"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Detectable in lymph nodes within 10 minutes (wait at least 15 minutes before mapping)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Has been detected for up to 30 hours after administration (mapping should be conducted within 15 hours following administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Radioactivity also distributes to liver, kidney, and bladder (accumulated radioactive dose reached a maximum at 1 hour after administration and was ~1% to 2% of injected dose in each tissue)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination at injection site: 1.8-3.1 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27529498"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lymphoseek</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lymphoseek</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lymphoseek</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lymphoseek</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lymphoseek</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10331526">
<a name="10331526"></a>Adelstein SJ. Administered Radionuclides in Pregnancy. <i>Teratology</i>. 1999;59(4):236-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/10331526/pubmed" id="10331526" target="_blank">10331526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). Revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24085499">
<a name="24085499"></a>Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. <i>Eur J Nucl Med Mol Imaging</i>. 2013;40(12):1932-1947. doi: 10.1007/s00259-013-2544-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/24085499/pubmed" id="24085499" target="_blank">24085499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Harding.1">
<a name="Harding.1"></a>Harding LK, Bossuyt S, Pellet C, et al. Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers. <i>Eur J Nucl Med</i>. 1995;22(5)BP17.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IAEA.1">
<a name="IAEA.1"></a>International Atomic Energy Agency. <i>IAEA Safety Standards for Protecting People and the Environment: Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide No. SSG-46</i>. IAEA; 2018. https://www​.iaea.org​/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11108925">
<a name="11108925"></a>International Commission on Radiological Protection (ICRP). Pregnancy and Medical Radiation. <i>Ann ICRP</i>. 2000;30(1):iii-viii, 1-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/11108925/pubmed" id="11108925" target="_blank">11108925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21331809">
<a name="21331809"></a>Leong SP, Kim J, Ross M, et al. A Phase 2 Study of <sup>99m</sup>Tc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer. <i>Ann Surg Oncol</i>. 2011;18(4):961-969.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/21331809/pubmed" id="21331809" target="_blank">21331809</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lymphoseek (technetium Tc 99m tilmanocept) injection [prescribing information]. Dublin, OH: Cardinal Health; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24051744">
<a name="24051744"></a>Marcinow AM, Hall N, Byrum E, et al. Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study. <i>JAMA Otolaryngol Head Neck Surg</i>. 2013;139(9):895-902.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/24051744/pubmed" id="24051744" target="_blank">24051744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Mountford PJ, Coakley AJ. A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations. <i>Nucl Med Commun</i>. 1989;10(1):15-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162938">
<a name="8162938"></a>Rubow S, Klopper J, Wasserman H, et al. The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry. <i>Eur J Nucl Med</i>. 1994;21(2):144-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/8162938/pubmed" id="8162938" target="_blank">8162938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SNM.1">
<a name="SNM.1"></a>Society of Nuclear medicine (SNM). Society of Nuclear Medicine procedure guideline for general imaging. Version 6.0. Revised 2010. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf. Accessed July 22, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23054107">
<a name="23054107"></a>Sondak VK, King DW, Zager JS, et al. Combined Analysis of Phase III Trials Evaluating [<sup>99m</sup>Tc] Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma. <i>Ann Surg Oncol</i>. 2013;20(2):680-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/23054107/pubmed" id="23054107" target="_blank">23054107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23504141">
<a name="23504141"></a>Wallace AM, Han LK, Povoski SP, et al. Comparative Evaluation of [<sup>99m</sup>Tc] Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials. <i>Ann Surg Oncol</i>. 2013;20(8):2590-2599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-pediatric-drug-information/abstract-text/23504141/pubmed" id="23504141" target="_blank">23504141</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131775 Version 10.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
